We demonstrated that the decrease of MITF and tyrosinase protein induces motility inhibition of C32 cells, which suggests the ability of those drugs to restore cancer cell sensitivity to treatment.
Marked down regulation of galectin-3 (∼5.5 folds) and tyrosinase (∼11.1 folds) by gene expression analysis substantiated by tyrosinase inhibition (IC<sub>50</sub> - 20.3 ± 1.26 μM Vs. Kojic acid - IC<sub>50</sub> - 24.1 ± 1.41 μM) and molecular docking studies strengthened the cancer modulatory property of marmelosin.
Bioluminescence imaging results show that TYR-LH<sub>2</sub> is fully competent for monitoring the dynamic changes of TYR in living cells and model animals and possesses the capability of discriminating melanocytes from other cell lines, thus offering a promising approach for investigation and diagnosis of melanoma cancer and other TYR-related diseases in vivo.
Furthermore, in vivo experiments showed that Fibroplex efficiently delivered tyrosinase and horseradish peroxidase, which led to hyper-pigmentation and tumor regression, respectively, suggesting its potential for therapeutic protein applications in hereditary diseases or cancer.
Thus, the finding that nonmutated tyrosinase peptides are immunogenic in a melanoma patient may provide the basis for the development of cancer immunotherapy, based on knowledge of synthetic tumor-associated peptide antigens.
Based upon familiar medical, biochemical, and energy principles this confronts cancer's pigmentary-depigmentary signs, glycolytic metabolism, elevated serum tyrosinase, defective collagen production, exposed membrane binding sites, and tyrosine's recent growth control role.